Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
WEBSep 12, 2024 · Gilead announced the results of a second pivotal Phase 3 trial showing that lenacapavir reduced HIV infections by 96% compared to background HIV incidence and was superior to Truvada for PrEP. The company plans to file for regulatory approval of lenacapavir for PrEP in 2025 and to make it available worldwide.
Twice-yearly shot proves successful at preventing HIV infection …
WEBJul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Full Efficacy and Safety Results for Gilead ... - Gilead Sciences
WEBJul 24, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.
Gilead reports updated data from trial of acclaimed HIV PrEP drug
WEB2 days ago · This news comes days after Gilead pledged its commitment to making its HIV drugs more accessible. The company signed royalty-free licensing agreements with six generic drugmakers to enhance access ...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
WEBIn a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from …
Gilead’s Innovative HIV Treatment Research Pipeline Aims to …
WEBMar 5, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.
New HIV drug can only offer hope of ending AIDS if all have …
WEBJul 10, 2024 · Gilead Sciences' trial results show that Lenacapavir, an injectable long-acting medicine, can prevent HIV infections better than oral PrEP. UNAIDS calls on Gilead to ensure equitable global access to the medicine through generic production and voluntary licensing agreements.
News Details - Gilead Sciences
WEBJun 20, 2024 · Gilead's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy and superiority to daily Truvada for HIV prevention in cisgender women. The trial, part of the comprehensive and diverse PURPOSE program, is the first to show zero infections in an HIV prevention study.
News Details - Gilead Sciences
WEB“This news is an important milestone in the work to help end the HIV epidemic as Sunlenca is now the only FDA-approved twice-yearly treatment for people with multi-drug resistant …
Gilead to Present Late-Breaking Data Highlighting Antiviral …
WEB1 day ago · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV ...